Discovery of novel TAOK2 inhibitor scaffolds from high-throughput screening

Alexander T. Piala, Radha Akella, Malia B. Potts, Stephanie A. Dudics-Giagnocavo, Haixia He, Shuguang Wei, Michael A. White, Bruce A. Posner, Elizabeth J. Goldsmith

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


The MAP3K (Mitogen Activated Protein Kinase Kinase Kinase) TAOK2 (Thousand-And-One Kinase 2) is an activator of p38 MAP kinase cascade that is up-regulated in response to environmental stresses. A synthetic lethal screen performed using a NSCLC (non-small cell lung cancer) cell line, and a second screen identifying potential modulators of autophagy have implicated TAOK2 as a potential cancer therapeutic target. Using a 200,000 compound high throughput screen, we identified three specific small molecule compounds that inhibit the kinase activity of TAOK2. These compounds also showed inhibition of autophagy. Based on SAR (structure–activity relationship) studies, we have predicted the modifications on the reactive groups for the three compounds.

Original languageEnglish (US)
Pages (from-to)3923-3927
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Issue number16
StatePublished - 2016


  • Autophagy
  • Drug discovery
  • High-throughput screening
  • Inhibitor
  • Kinase
  • MAP3K

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry


Dive into the research topics of 'Discovery of novel TAOK2 inhibitor scaffolds from high-throughput screening'. Together they form a unique fingerprint.

Cite this